ASX-listed medicinal cannabis company, MGC Pharmaceuticals, has inked a distribution agreement to produce and supply its cannabinoid medicines to South American based Anden Bio Naturals SA, a company that pioneered the legal import of cannabis-based products into Peru via a tender with its Government’s Ministry of Health.

The exclusive five-year agreement will give MGC access to Anden’s Peruvian and Bolivian industry networks containing over 7,500 pharmacies, private clinics and an oncological private insurance system that has over one million listed clients.

Co-founder and Managing Director of MGC Pharma, Roby Zomer said: “This closely follows our entry to the Latin American market in November 2019, when MGC Pharma’s products became available in Brazil and in December receiving formal approval for the sale of CannEpil in Ireland.”

Read more at : https://thewest.com.au/business/public-companies/mgc-to-distribute-medical-cannabis-in-south-america-c-669094